Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

NASDAQ:ROIV - BMG762791017 - Common Stock

11.84 USD
+0.2 (+1.72%)
Last: 8/26/2025, 8:00:27 PM
11.89 USD
+0.05 (+0.42%)
Pre-Market: 8/27/2025, 8:41:48 AM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ROIV. ROIV was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability. ROIV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ROIV has reported negative net income.
In the past year ROIV has reported a negative cash flow from operations.
ROIV had negative earnings in 4 of the past 5 years.
ROIV had a negative operating cash flow in each of the past 5 years.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

The Return On Assets of ROIV (-3.16%) is better than 87.75% of its industry peers.
ROIV has a better Return On Equity (-3.67%) than 90.13% of its industry peers.
Industry RankSector Rank
ROA -3.16%
ROE -3.67%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

ROIV has a Gross Margin of 96.86%. This is amongst the best in the industry. ROIV outperforms 95.80% of its industry peers.
ROIV's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ROIV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

9

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ROIV has less shares outstanding
ROIV has more shares outstanding than it did 5 years ago.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

ROIV has an Altman-Z score of 6.90. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.90, ROIV belongs to the top of the industry, outperforming 80.99% of the companies in the same industry.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.9
ROIC/WACCN/A
WACC9.04%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

ROIV has a Current Ratio of 33.47. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 33.47, ROIV belongs to the best of the industry, outperforming 97.81% of the companies in the same industry.
ROIV has a Quick Ratio of 33.47. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 33.47, ROIV belongs to the top of the industry, outperforming 97.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 33.47
Quick Ratio 33.47
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.09% over the past year.
The Revenue for ROIV has decreased by -11.19% in the past year. This is quite bad
Measured over the past years, ROIV shows a very negative growth in Revenue. The Revenue has been decreasing by -15.56% on average per year.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-96.06%

3.2 Future

ROIV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.65% yearly.
ROIV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.30% yearly.
EPS Next Y-466.44%
EPS Next 2Y-133.67%
EPS Next 3Y-51.56%
EPS Next 5Y33.65%
Revenue Next Year-73.25%
Revenue Next 2Y0.98%
Revenue Next 3Y83.81%
Revenue Next 5Y86.3%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ROIV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ROIV's earnings are expected to decrease with -51.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-133.67%
EPS Next 3Y-51.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROIVANT SCIENCES LTD

NASDAQ:ROIV (8/26/2025, 8:00:27 PM)

Premarket: 11.89 +0.05 (+0.42%)

11.84

+0.2 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)N/A N/A
Inst Owners72.34%
Inst Owner ChangeN/A
Ins Owners1.88%
Ins Owner Change6.27%
Market Cap8.09B
Analysts84.71
Price Target19.89 (67.99%)
Short Float %9.04%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)93.91%
Min EPS beat(2)7.69%
Max EPS beat(2)180.12%
EPS beat(4)3
Avg EPS beat(4)78.61%
Min EPS beat(4)-18.6%
Max EPS beat(4)180.12%
EPS beat(8)5
Avg EPS beat(8)38.61%
EPS beat(12)7
Avg EPS beat(12)23.81%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-54.76%
Min Revenue beat(2)-86.28%
Max Revenue beat(2)-23.24%
Revenue beat(4)1
Avg Revenue beat(4)-32.25%
Min Revenue beat(4)-91.09%
Max Revenue beat(4)71.59%
Revenue beat(8)3
Avg Revenue beat(8)-13.21%
Revenue beat(12)6
Avg Revenue beat(12)-2.12%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.65%
PT rev (3m)15.68%
EPS NQ rev (1m)-10.71%
EPS NQ rev (3m)-34.78%
EPS NY rev (1m)-7.62%
EPS NY rev (3m)-10.71%
Revenue NQ rev (1m)-5.82%
Revenue NQ rev (3m)31.53%
Revenue NY rev (1m)-14.19%
Revenue NY rev (3m)-10.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 278.29
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.04
BVpS6.86
TBVpS6.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.16%
ROE -3.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.86%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.68%
Cap/Sales 15.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.47
Quick Ratio 33.47
Altman-Z 6.9
F-Score4
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
EPS Next Y-466.44%
EPS Next 2Y-133.67%
EPS Next 3Y-51.56%
EPS Next 5Y33.65%
Revenue 1Y (TTM)-11.19%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-96.06%
Revenue Next Year-73.25%
Revenue Next 2Y0.98%
Revenue Next 3Y83.81%
Revenue Next 5Y86.3%
EBIT growth 1Y-0.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.9%
EBIT Next 3Y8.21%
EBIT Next 5YN/A
FCF growth 1Y-10.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.69%
OCF growth 3YN/A
OCF growth 5YN/A